SteadyMed, a pharmaceutical company whose focus is the development of products to treat orphan diseases with unmet clinical needs, has announced promising results from an animal study evaluating the efficacy of its lead drug product Trevyent® in the reduction of the pain associated with the use of United Therapeutics’ Remodulin® to treat pulmonary…
In a new study, researchers determined that elevated serum bilirubin levels and a low 6-minute walk distance are predictors of poor prognosis in patients with inoperable chronic thromboembolic pulmonary hypertension. The research — whose findings appear to offer important disease prognosis markers — is titled “Serum Bilirubin and 6-min Walk Distance as Prognostic Predictors…
Over the last decade, new oral therapy agents in the form of pills used for the management and treatment of pulmonary arterial hypertension (PAH) have been integrated and improved, such as ERAs, PDE-5 inhibitors, and prostacyclin analogs. Oral PAH therapy is a positive development for patients, since it makes compliance with…
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company that focuses on the development and commercialization of drugs for the treatment of rare diseases and conditions with ineffective treatments, announced that ubenimex, a drug developed as a pulmonary arterial hypertension (PAH) therapy, has been granted Orphan Drug Status by the U.S. Food and Drug Administration (FDA). Ubenimex, also…
A new retrospective study of computed tomographies of chronic obstructive pulmonary disease (COPD) patients shows that chest CT has value as a diagnostic tool for COPD and its comorbidity pulmonary hypertension (PH). The research paper, entitled “Computed tomography measurement of pulmonary artery for diagnosis of COPD and its comorbidity…
In a new study, researchers aimed to evaluate nerve distribution around the pulmonary artery — the effect of pulmonary artery denervation on an acute pulmonary hypertension porcine model — both in terms of arterial pressure and artery histology. The research paper, entitled “Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure…
In a new study, researchers investigated if 3-D phase-contrast observations of wall shear stress (WSS) and oscillatory shear index (OSI) could effectively diagnose and evaluate pulmonary arterial hypertension (PAH) in patients, potentially leading to a markedly less invasive but accurate way of early disease diagnosis and management. The research paper, entitled “Low WSS and…
In a new retrospective study, researchers show that a procedure called “palliative Senning” improves arterial oxygenation and life quality in children with congenital heart diseases and severe pulmonary hypertension (PH). The research paper, entitled “Palliative Senning in the Treatment of Congenital Heart Disease with Severe Pulmonary Hypertension,” was published in…
Complexa Inc., a biopharmaceutical company developing therapies to treat fibrosis and inflammation-related diseases, announced the successful completion of a Phase 1 clinical program of its lead drug candidate CXA-10, and the beginning of preparations for Phase 2 clinical trials for focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH) in 2016. The announcement builds…
Boehringer Ingelheim Pharmaceuticals, Inc. and the Pulmonary Fibrosis Foundation (PFF) have announced a five-year partnership in an effort to raise awareness for the disease and provide patients with disease education. Boehringer Ingelheim’s investment will also contribute to research funding of early diagnosis techniques and new therapies. Pulmonary Fibrosis (PF),…
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company that develops and commercializes drugs for the treatment of orphan diseases and conditions with ineffective current treatments, announced a new license agreement with a leading Japanese pharmaceutical company, Nippon Kayaku. Eiger BioPharmaceuticals aims to develop Nippon Kayaku’s therapeutic drug Bestatin™ (ubenimex) for the treatment of pulmonary…
Right ventricular (RV) dysfunction is a characteristic of several disorders such as pulmonary hypertension, congenital heart disease and cardiomyopathy, making RV function evaluation key to effective prognosis and diagnostic value in such disorders. However, diagnosis through RV function is challenging due to anatomical configuration of the RV. Right ventricular outflow tract (RVOT)…
Get regular updates to your inbox.